Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nateglinide Add-on to Basal Insulin Glargine in Type 2 Diabetes
NCT00402909Phase 4Completed
- Sponsor
- Novartis
- Start
- Nov 2006
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Nateglinide Arm with Placebo Arm (2 arms). Primary endpoint: Change from baseline in hemoglobin A1c at 16 weeks. Started Nov 2006; status: completed.
02
Drugs
nateglinide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00402909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00402909.